LAMEA Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report by Type (Proteomic, Genomic, Metabolomic), Application (Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis), Country and Growth Forecast, 2022-2028

The Latin America, Middle East and Africa Neurological Biomarkers Market should witness market growth of 17.6% CAGR during the forecast period (2022-2028).

Innovative biomarkers, which are biological markers that objectively evaluate and quantify physiological or pathophysiological processes or pharmacological responses to treatment, have been proposed to assist in the assessment and treatment of patients with neurological abnormalities beyond the scope of currently accepted practice. Rapid scientific and technical progress has made it possible to accurately and economically measure novel biomarkers.

Evidence points to a potential range of clinical applications, including refining the decision criteria for early diagnosis and risk stratification, assisting in disease monitoring, and serving as submitters in experimental studies and clinical trials.

Additionally, biomarkers may accurately capture the various components of illness heterogeneity and etiology, assisting in patient characterization, guiding focused, customized treatments, and forecasting intervention response outcomes. However, even though many possible biomarkers have been put forth and thoroughly examined, relatively few of them are currently used in ordinary clinical practice, and the search for new markers for brain injury is still ongoing.

In South Africa, there were 3.171 million (5.4%) people who were 65 or older in 2019, and this number is expected to rise to 4.404 million (6.7%) by 2030, according to the World Population Ageing 2019. This is expected to raise the number of dementia patients over time, spark the attention of current players, and motivate them to boost their investments in the country. The use of neurological biomarkers treatment in this area has been accelerated by the rising number of neurological biomarkers market.

The Brazil market dominated the LAMEA Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $220.2 Million by 2028. The Argentina market is poised to grow at a CAGR of 18.2% during (2022-2028). Additionally, The UAE market would exhibit a CAGR of 17.2% during (2022-2028).

Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.

Scope of the Study

By Type

• Proteomic
• Genomic
• Metabolomic
• Others

By Application

• Alzheimer's Disease
• Parkinson’s Disease
• Multiple Sclerosis

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• F.HOFFMANN-LA ROCHE LTD.
• Bio-Rad Laboratories, Inc.
• Merck Group
• PERKINELMER INC.
• Shimadzu corporation
• Thermo Fisher Scientific, Inc.
• Quanterix Corporation
• Neuro-Bio Ltd.
• BioMérieux S.A.
• Myriad Genetics, Inc.

Unique Offerings

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free